Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is demonstrating promising results in early human assessments . Recent research indicates https://getidealist.com/story23277426/retatrutide-emerging-studies-and-projected-therapeutic-applications